Biocept Inc (BIOCQ)

Biocept, Inc. is a common stock listing on OTC Markets for a biotechnology company focused on molecular oncology diagnostics. The company developed and commercialized laboratory assays intended to detect rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid in the United States. Its testing portfolio was designed to help healthcare providers identify cancer-related alterations that may support targeted therapy decisions at diagnosis, during progression, and in monitoring for resistance mechanisms. Biocept’s services covered several solid tumor indications, including breast, non-small cell lung, gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancers, and it also provided CSF-based testing and research services for physicians and life sciences customers. Founded in 1997 and based in San Diego, California, Biocept filed for voluntary Chapter 7 liquidation in October 2023.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.